celecoxib + pregabalin + acetaminophen + tramadol + oxycodone

The combination of celecoxib, pregabalin, acetaminophen, tramadol, and oxycodone is a multimodal analgesic regimen used as a standardized background therapy in clinical research, specifically for managing postoperative pain in patients with central sensitization undergoing total knee arthroplasty (TKA). This regimen, evaluated in trials sponsored by The Catholic University of Korea (such as NCT02600247), employs a multi-pronged approach to pain control: celecoxib provides anti-inflammatory effects via selective COX-2 inhibition; pregabalin modulates neurotransmitter release by binding to the alpha-2-delta subunit of voltage-gated calcium channels; acetaminophen and tramadol (often administered as a fixed-dose combination like Ultracet ER) provide non-opioid and weak opioid analgesia with additional SNRI activity; and oxycodone serves as a potent mu-opioid receptor agonist for breakthrough or severe pain. This protocol is designed to optimize analgesia while potentially reducing the reliance on high-dose single-agent opioids in the context of osteoarthritis-related surgery.

Brand names

CelebrexLyricaUltracet ERIrcodon

Other names

multimodal analgesic background regimenroutine pain control protocol